| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Ipratropium-d7 bromide targets muscarinic acetylcholine receptors (M1, M2, M3 subtypes) in the airways. It acts as a competitive antagonist, blocking the action of acetylcholine and reducing bronchial smooth muscle tone. The d7 label does not alter receptor binding, but the labeled compound is used primarily as an analytical standard, not for activity studies.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to alter the pharmacokinetic and metabolic characteristics of medications, deuteration has drawn attention[1].
Unlabeled ipratropium bromide inhibits carbachol-induced contraction of isolated guinea pig tracheal rings (cell-free tissue bath assay) with an IC50 in the low nanomolar range. It also displaces [3H]-N-methylscopolamine from M3 receptors in membrane preparations (Kd ~0.2 nM). Ipratropium-d7 is not used in these assays; it is used for quantification. |
| ln Vivo |
In cell-based assays (e.g., human bronchial epithelial cells or smooth muscle cells), unlabeled ipratropium (0.1-100 nM) inhibits methacholine-induced calcium flux and ERK phosphorylation. It also blocks acetylcholine-induced bronchoconstriction in isolated perfused lungs. Ipratropium-d7 is used as an internal standard to measure drug concentrations in cell lysates or culture media by LC-MS/MS.
|
| Enzyme Assay |
For analytical method development, Ipratropium-d7 bromide is used as an internal standard. A calibration curve is prepared by spiking unlabeled ipratropium bromide into blank plasma or buffer with a fixed concentration of the d7 standard. Samples are extracted by protein precipitation or solid-phase extraction and analyzed by LC-MS/MS. The peak area ratio (unlabeled/d7) is used for quantification. No receptor binding assay is performed with the labeled standard.
|
| Cell Assay |
Bronchial epithelial cells or lung slices are treated with unlabeled ipratropium bromide (0.1-100 nM) for 15-60 minutes. At the end of the experiment, cells are lysed, and ipratropium concentrations are quantified by LC-MS/MS using Ipratropium-d7 as the internal standard. This allows measurement of cellular accumulation. Parallel functional assays (e.g., calcium flux) are performed to correlate concentration with effect.
|
| Animal Protocol |
In animal studies, Ipratropium-d7 can be co-administered with unlabeled ipratropium as a tracer, or used as an internal standard in bioanalysis. Rats or guinea pigs are dosed with ipratropium bromide via inhalation or intravenous injection (e.g., 1-10 ug/kg). Blood and lung tissue are collected at multiple time points. Samples are analyzed by LC-MS/MS with Ipratropium-d7 as the internal standard to determine pharmacokinetic parameters (Cmax, AUC, half-life).
|
| ADME/Pharmacokinetics |
Ipratropium-d7 has identical PK properties to unlabeled ipratropium. Ipratropium bromide is poorly absorbed after oral administration; it is administered by inhalation. The systemic bioavailability is low (2-5%). After inhalation, the drug acts locally in the lungs and is rapidly cleared from plasma (half-life 2-4 hours). It is metabolized by esterases and excreted in urine and feces. The d7 label does not affect these properties.
|
| Toxicity/Toxicokinetics |
Ipratropium-d7 is used in trace amounts and does not contribute to toxicity. The unlabeled ipratropium is well-tolerated at therapeutic doses. Common adverse effects include dry mouth, cough, and throat irritation. Systemic side effects (e.g., tachycardia, urinary retention) are rare due to low bioavailability. The deuterium label does not alter the safety profile. No additional toxicity is expected.
|
| References |
|
| Additional Infomation |
Ipratropium bromide (Atrovent®) is an FDA-approved anticholinergic bronchodilator for COPD and asthma. Ipratropium-d7 is a research-grade stable isotope-labeled internal standard intended for non-clinical analytical use only. It is not for human therapeutic use. The compound is supplied as a powder, stored at -20degC. The d7 label has high isotopic purity (≥98%). It is commonly used in pharmacokinetic and bioequivalence studies.
|
| Molecular Formula |
C22H27D7BRNO3
|
|---|---|
| Molecular Weight |
447.46
|
| Related CAS # |
Ipratropium bromide;22254-24-6;Ipratropium bromide hydrate;66985-17-9
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2348 mL | 11.1742 mL | 22.3484 mL | |
| 5 mM | 0.4470 mL | 2.2348 mL | 4.4697 mL | |
| 10 mM | 0.2235 mL | 1.1174 mL | 2.2348 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
